Carlsmed Q1 Revenue Surges 58% to $16.12M, EPS Loss Narrows Sharply
summarizeSummary
Carlsmed, Inc. reported strong first-quarter 2026 results, with revenue increasing 58.2% year-over-year to $16.12 million, driven by higher procedure volumes and commercial expansion. While the company's net loss widened to $(8.70) million, the diluted loss per share significantly narrowed to $(0.32) from $(1.47) in the prior-year period, indicating improved per-share profitability. This Q1 update, following the fiscal year 2025 10-K, demonstrates continued operational momentum, including the recent commercial launch of aprevo Cervical and reduced manufacturing lead times. The robust revenue growth and substantial improvement in EPS loss are positive indicators for the company's trajectory in the personalized spine surgery market. Investors should monitor continued sales force expansion and product adoption for future growth.
At the time of this announcement, CARL was trading at $9.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $242.9M. The 52-week trading range was $8.50 to $17.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.